Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt N/A
UNIS's Cash to Debt is ranked higher than
76% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. UNIS: N/A )
Ranked among companies with meaningful Cash to Debt only.
UNIS' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.67 Max: N/A
Current: N/A
Equity to Asset -0.42
UNIS's Equity to Asset is ranked lower than
97% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. UNIS: -0.42 )
Ranked among companies with meaningful Equity to Asset only.
UNIS' s Equity to Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.53 Max: 0.79
Current: -0.42
-0.42
0.79
F-Score: 2
Z-Score: -7.57
M-Score: -4.83
WACC vs ROIC
2.87%
-191.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -602.25
UNIS's Operating margin (%) is ranked lower than
95% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. UNIS: -602.25 )
Ranked among companies with meaningful Operating margin (%) only.
UNIS' s Operating margin (%) Range Over the Past 10 Years
Min: -2225.96  Med: -561.23 Max: -235.51
Current: -602.25
-2225.96
-235.51
Net-margin (%) -714.65
UNIS's Net-margin (%) is ranked lower than
94% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. UNIS: -714.65 )
Ranked among companies with meaningful Net-margin (%) only.
UNIS' s Net-margin (%) Range Over the Past 10 Years
Min: -2303.97  Med: -502.97 Max: 276.17
Current: -714.65
-2303.97
276.17
ROA (%) -97.02
UNIS's ROA (%) is ranked lower than
96% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. UNIS: -97.02 )
Ranked among companies with meaningful ROA (%) only.
UNIS' s ROA (%) Range Over the Past 10 Years
Min: -103.3  Med: -61.11 Max: 43.05
Current: -97.02
-103.3
43.05
ROC (Joel Greenblatt) (%) -134.44
UNIS's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.53 vs. UNIS: -134.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
UNIS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -156.25  Med: -99.22 Max: 137.13
Current: -134.44
-156.25
137.13
Revenue Growth (3Y)(%) 12.80
UNIS's Revenue Growth (3Y)(%) is ranked higher than
83% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.10 vs. UNIS: 12.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
UNIS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.3  Med: 12.80 Max: 82.8
Current: 12.8
-48.3
82.8
EBITDA Growth (3Y)(%) 1.40
UNIS's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. UNIS: 1.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
UNIS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.6  Med: 1.50 Max: 157
Current: 1.4
-9.6
157
EPS Growth (3Y)(%) 1.50
UNIS's EPS Growth (3Y)(%) is ranked lower than
59% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. UNIS: 1.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
UNIS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.6  Med: 4.25 Max: 152.6
Current: 1.5
-5.6
152.6
» UNIS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-09-14)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

UNIS Guru Trades in Q2 2015

Jim Simons 27,774 sh (New)
Ron Baron 333,477 sh (-52.49%)
» More
Q3 2015

UNIS Guru Trades in Q3 2015

Ron Baron Sold Out
Jim Simons Sold Out
» More
Q4 2015

UNIS Guru Trades in Q4 2015

Jim Simons 352,501 sh (New)
» More
Q1 2016

UNIS Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with UNIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:HBIOV, TSE:7702, BSP:CREM3, HKSE:00899, BKK:TOG, NAS:SIEN » details
Traded in other countries:UNS.Australia, 4UL1.Germany, UNISZ.USA,
Unilife Corp is a designer, manufacturer and supplier of injectable drug delivery systems. Its product include pre-filled syringes, wearable injectors, disposable & reusable auto-injectors, drug reconstitution delivery systems & other systems.

Unilife Corp was incorporated in Delaware on July 2, 2009 as a wholly owned subsidiary of UMSL. The Company is designer, manufacturer and supplier of injectable drug delivery systems that can enhance and differentiate the injectable drugs, biologics and vaccines, or collectively, injectable therapies, of pharmaceutical and biotechnology customers. Its products include pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems for the targeted delivery of injectable therapies. These products are designed for sale directly to pharmaceutical and biotechnology companies who are expected to supply them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Other products like reusable auto-injectors and certain systems for targeted drug delivery, are designed to either be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly by company to a health care provider or end user without having the device pre-filled by a pharmaceutical company. The Company's customers include Sanofi, MedImmune, AbbVie, Novartis and Hikma. The Company sells its products directly to pharmaceutical and biotechnology companies who incorporate them into the drug-device combination product that is supplied pre-filled and ready for administration by end-users such as health-care providers or patients. It competes with both public and private, which include Becton, Dickinson and Company, or BD, SCHOTT forma vitrum AG, Gerresheimer Bünde GmbH, West Pharmaceutical Services, Inc., Medtronic MiniMed, Inc., Insulet Corporation, and Ypsomed Group. As of July 2015, it had approximately 180 issued patents relating to its product platforms across more than 24 jurisdictions, including the U.S., the European Union, Australia, Japan, Israel, and China.

Ratios

vs
industry
vs
history
P/S 3.15
UNIS's P/S is ranked lower than
51% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. UNIS: 3.15 )
Ranked among companies with meaningful P/S only.
UNIS' s P/S Range Over the Past 10 Years
Min: 2.69  Med: 31.10 Max: 99.71
Current: 3.15
2.69
99.71
EV-to-EBIT -1.47
UNIS's EV-to-EBIT is ranked lower than
99.99% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.36 vs. UNIS: -1.47 )
Ranked among companies with meaningful EV-to-EBIT only.
UNIS' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.6  Med: -5.80 Max: -1.3
Current: -1.47
-19.6
-1.3
EV-to-EBITDA -1.56
UNIS's EV-to-EBITDA is ranked lower than
99.99% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.91 vs. UNIS: -1.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
UNIS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.9  Med: -6.50 Max: -1.3
Current: -1.56
-21.9
-1.3
Current Ratio 0.66
UNIS's Current Ratio is ranked lower than
95% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. UNIS: 0.66 )
Ranked among companies with meaningful Current Ratio only.
UNIS' s Current Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.65 Max: 8.01
Current: 0.66
0.32
8.01
Quick Ratio 0.66
UNIS's Quick Ratio is ranked lower than
89% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. UNIS: 0.66 )
Ranked among companies with meaningful Quick Ratio only.
UNIS' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.61 Max: 7.77
Current: 0.66
0.32
7.77
Days Sales Outstanding 76.76
UNIS's Days Sales Outstanding is ranked lower than
70% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.25 vs. UNIS: 76.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
UNIS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.71  Med: 49.61 Max: 577.21
Current: 76.76
0.71
577.21

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.10
UNIS's Price/Median PS Value is ranked higher than
98% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. UNIS: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
UNIS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 1.20 Max: 2.95
Current: 0.1
0.14
2.95
Earnings Yield (Greenblatt) (%) -68.00
UNIS's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. UNIS: -68.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
UNIS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -77.26  Med: 0.00 Max: 0
Current: -68
-77.26
0

More Statistics

Revenue (TTM) (Mil) $14.06
EPS (TTM) $ -8.26
Beta-0.84
Short Percentage of Float13.27%
52-Week Range $2.31 - 27.70
Shares Outstanding (Mil)0.17
» More Articles for UNIS

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, TRCR, SHOR, IEC, UNIS Feb 10 2012 
Weekly CEO Buys Highlight: IDCC, MWW, UNIS Jan 29 2012 
Weekly CEO Buys Highlight: TRNO, UNIS, GFN Jan 21 2012 
Weekly CEO Buys Highlight: UNIS, TRNO, WINA, SXC, CTFO Jan 14 2012 
Weekly CEO Buys Highlight: UNIS, ESL, TREE, TPGI, VAC Jan 08 2012 
Weekly CEO Buys Highlight: BFS, NCT, NL, UNIS, MSCI Oct 01 2011 
Weekly CEO Buys Highlight: RCL, CIT, PNK, EXE, UNIS Aug 27 2011 
Weekly CEO Buys Highlight: DELL, DEER, BGCP, UNIS, KSWS Mar 19 2011 
Unilife Corp. (UNIS) CEO Alan Shortall buys 105,452 Shares Mar 17 2011 
Unilife Corp. Reports Operating Results (10-Q) Feb 14 2011 

More From Other Websites
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... May 28 2016
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Unilife... May 27 2016
SHAREHOLDER NOTICE: Lundin Law PC Announces Investigation Of Unilife Corporation And Advises... May 27 2016
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Unilife... May 27 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Unilife... May 27 2016
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Investigation of Unilife Corporation and Advises... May 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Unilife Corporation of a Class... May 27 2016
INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Unilife Corporation And... May 26 2016
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Unilife Corporation May 26 2016
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Unilife... May 25 2016
Harwood Feffer LLP Announces Investigation of Unilife Corporation May 25 2016
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Unilife... May 25 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Unilife Corporation May 25 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unilife... May 25 2016
SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims Against Unilife... May 24 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into... May 24 2016
IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Unilife... May 24 2016
Glancy Prongay & Murray Commences Investigation on Behalf of Unilife Corporation Investors May 24 2016
UNILIFE CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... May 23 2016
Unilife Corporation Announces Receipt of Deficiency Letter from NASDAQ May 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)